logo

Kala Pharmaceuticals, Inc. (KALA)



Trade KALA now with
  Date
  Headline
11/8/2018 7:45:06 AM Kala Pharmaceuticals Q3 Net Loss $15.6 Mln Or $0.63/Shr Vs Net Loss $10.2 Mln Or $0.56/Shr Last Year
10/16/2018 8:06:25 AM Kala Pharma Submits NDA For KPI-121 0.25% For Dry Eye Disease
10/3/2018 8:04:17 AM Kala Pharmaceuticals Prices Public Offering Of 7.50 Mln Shares At $8.25 Per Share
8/9/2018 7:13:54 AM Kala Pharmaceuticals Q2 Net Loss $14.6 Mln Or $0.60/shr Vs. Net Loss $11.0 Mln Or $9.30/shr Last Year
7/31/2018 8:06:11 AM Kala Pharma Unveils Dosing Of First Patient In Phase 3 STRIDE 3 Trial Of KPI-121 0.25% In Patients With Dry Eye
6/20/2018 7:20:43 AM Wedbush Reiterates Kala Pharmaceuticals, Inc. (KALA) At Outperform With $47 Price Target
5/15/2018 2:20:56 PM Wedbush Is Increasing Kala Pharmaceuticals, Inc. (KALA) Q1 19 Estimate To -0.64 From -0.65
5/15/2018 2:20:40 PM Wedbush Is Raising Kala Pharmaceuticals, Inc. (KALA) FY18 Estimate To -2.01 From -2.10
5/15/2018 2:20:20 PM Wedbush Is Increasing Kala Pharmaceuticals, Inc. (KALA) Q4 18 Estimate To -0.53 From -0.56
5/15/2018 2:20:11 PM Wedbush Is Raising Kala Pharmaceuticals, Inc. (KALA) Q3 18 Estimate To -0.51 From -0.53
5/15/2018 2:19:22 PM Wedbush Is Increasing Kala Pharmaceuticals, Inc. (KALA) Q2 18 Estimate To -0.50 From -0.52
5/15/2018 2:18:59 PM Wedbush Reiterates Kala Pharmaceuticals, Inc. (KALA) At Outperform With $47 Up From $46 Price Target
5/10/2018 7:10:44 AM Kala Pharma Q1 Net Loss $11.3 Mln Or $0.46/shr Vs. Net Loss $9.8 Mln Or $8.26/shr Last Year
5/9/2018 5:06:00 PM Kala Strengthens Commercial Organization In Preparation For First Product Launch
4/18/2018 8:38:28 AM Wedbush Is Increasing Kala Pharmaceuticals, Inc. (KALA) 4Q18 Estimate To -0.56 From -0.61